| Similar Articles |
|---|
 |
The Motley Fool
February 15, 2006
Stephen D. Simpson |
A Play on the Building Blocks of R&D Sigma-Aldrich might be suitable for those looking to play biological R&D without picking a specific pharma or biotech stock.   |
The Motley Fool
September 27, 2006
Ralph Casale |
Qiagen: Biotech Support Is this biotech industry leader an attractive investment? While this is a quality company operating an attractive business, investors may want to wait for a better price before adding it to a portfolio. |
The Motley Fool
August 14, 2007
Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
The Motley Fool
June 2, 2006
Stephen D. Simpson |
Pall Still Looks Clogged Weak margins and poor returns on capital don't make for a compelling case for this leading player in filtration and separation equipment and technology. Investors, take note. |
The Motley Fool
February 14, 2006
Stephen D. Simpson |
Looking for a Hook at Fisher Scientific Growth and market share are great, but return on invested capital tells the tale in the end. Investors, think twice before putting your money with this one. |
The Motley Fool
September 15, 2005
Stephen D. Simpson |
CLARCOR Filters Out More Profit With many investors expecting further merger and acquisition activity in the filtration space, multiples have remained pretty high across the board. |
The Motley Fool
December 7, 2005
Stephen D. Simpson |
Why Pay for Pall? Filtration is still a good business, but this firm's modest performance doesn't impress shareholders. |
The Motley Fool
September 14, 2006
Anders Bylund |
Margins Are Your Pals, Pall How will the filtration company revive flagging growth and thinning margins? Investors, take note. |
